ADCT Faces Investor Investigation Following Safety Concerns in Clinical Trial Data
Market Chameleon (Fri, 16-Jan 11:11 AM)
ADC Therapeutics Reports 89.8% Response Rate for ZYNLONTA Combo in DLBCL—Will This Change Treatment Expectations?
Market Chameleon (Thu, 4-Dec 10:08 AM)
